Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM)

被引：0
|
作者：
Bayle, Arnaud
Belcaid, Laila
Cousin, Sophie
Palmieri, Lola-Jade
Spalato, Mariella
Aldea, Mihaela
Vasseur, Damien
Alame, Melissa
Soubeyran, Isabelle
Nicotra, Claudio
Ngocamus, Maud
Ponce, Santiago
Loriot, Yohann
Besse, Benjamin
Lacroix, Ludovic
Rouleau, Etienne
Oxnard, Geoffrey R.
Barlesi, Fabrice
Andre, Fabrice
Italiano, Antoine
机构：
[1] Gustave Roussy Canc Ctr, Villejuif, France
[2] Rigshospitalet, Copenhagen, Denmark
[3] Inst Bergonie, Early Phase Clin Trials Unit & Thorac Unit, Bordeaux, France
[4] Inst Bergonie, Bordeaux, France
[5] Gustave Roussy, Dept Canc Med, Villejuif, France
[6] Gustave Roussy, Villejuif, France
[7] Inst Bergonie, Dept Biopathol, Mol Pathol Unit, Bordeaux, France
[8] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[9] Gustave Roussy, DITEP Drug Dev Dept, Villejuif, France
[10] Univ Paris Saclay, Gustave Roussy, DITEP, Villejuif, France
[11] Gustave Roussy, Dept Pathol & Med Biol, Canc Genet Lab, Villejuif, France
[12] Fdn Med, Cambridge, MA USA
[13] Univ Paris Sud, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3016
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI
    Taghizadeh, Hossein
    Unseld, Matthias
    Spalt, Martina
    Mader, Robert M.
    Mullauer, Leonhard
    Fuereder, Thorsten
    Raderer, Markus
    Sibilia, Maria
    Hoda, Mir Alireza
    Aust, Stefanie
    Polterauer, Stephan
    Lamm, Wolfgang
    Bartsch, Rupert
    Preusser, Matthias
    Kautzky-Willer, A.
    Prager, Gerald W.
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 17
  • [22] Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09)
    Chae, Heejung
    Koo, Harim
    Kim, Sun Young
    Park, Sook Ryun
    Yoon, Shinkyo
    Ryu, Min-Hee
    Lee, Soohyeon
    Kim, Tae-Yong
    Kim, Tae Min
    Han, Sae-Won
    Lee, Se-Hoon
    Jung, Hyun Ae
    Kim, Hye Ryun
    Jung, Minkyu
    Lee, Gyeong-Won
    Ahn, Mi Sun
    Yun, Hongseok
    Choi, Yoon-La
    Lee, Sejoon
    Kim, Jee Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies
    Moriarty, A.
    Flores, J.
    Peskin, A.
    Lynch, M.
    Papadopoulos, K.
    Lakhani, N.
    Sharma, M.
    Drengler, R.
    Szender, J.
    Rasco, D.
    Patnaik, A.
    Bucheit, A.
    Wick, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S14 - S14
  • [24] A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
    Le Saux, Olivia
    Italiano, Antoine
    Spaeth, Dominique
    Heudel, Pierre
    Filleron, Thomas
    Albiges, Laurence
    Bachelot, Thomas
    Goncalves, Anthony
    Pierga, Jean-Yves
    Barlesi, Fabrice
    Boige, Valerie
    Lebbe, Celeste
    Mortier, Laurent
    Frenel, Jean Sebastien
    Tredan, Olivier
    Jimenez, Marta
    Legrand, Francois
    Ferte, Charles
    CANCER RESEARCH, 2018, 78 (13)
  • [25] A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesanchymal tumors: A retrospective study from the GSF-GETO
    Bay, J.
    Le Cesne, A.
    Cioffi, A.
    Penel, N.
    Duffaud, F.
    Cupissol, D.
    Piperno-Neumann, S.
    Cropet, C.
    Bouclier, L.
    Ray-Coquard, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Preliminary results MATCH-R trial, a prospective trial to study acquired resistance of tumors from patients treated with molecular targeted agents or immunotherapy
    Besse, B.
    Lacroix, L.
    Michiels, S.
    Friboulet, L.
    Rouleau, E.
    Auger, N.
    Adam, J.
    Nicotra, C.
    Bigot, L.
    Judde, J. G.
    Angevin, E.
    Planchard, D.
    Loriot, Y.
    Tselikas, L.
    Andre, F.
    Soria, J. C.
    Solary, E.
    Vassal, G.
    Massard, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E118 - E118
  • [27] Erlotinib plus bevacizumab in patients with metastatic solid tumors with EGFR amplification: Results from the KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced solid tumors, KCSG AL 22-09)
    Lee, J. W.
    Lee, Y-g.
    Lee, G-w.
    Jung, H. A.
    Kim, K-p.
    Kim, T-y.
    Ryu, H.
    Ryu, M. H.
    Ahn, M. S.
    Yun, H.
    Ahn, S.
    Shim, H. S.
    Kim, J.
    Sim, J.
    Kim, S. Y.
    Kim, J. H.
    Lee, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1580 - S1580
  • [28] Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09
    Kim, Sun Young
    Kim, Jee Hyun
    Kim, Tae-Yong
    Park, Sook Ryun
    Yoon, Shinkyo
    Lee, Soohyeon
    Lee, Se-Hoon
    Kim, Tae Min
    Han, Sae-Won
    Kim, Hye Ryun
    Yun, Hongseok
    Lee, Sejoon
    Kim, Jihun
    Choi, Yoon-La
    Choi, Kui Son
    Chae, Heejung
    Ryu, Hyewon
    Lee, Gyeong-Won
    Zang, Dae Young
    Ahn, Joong Bae
    BMC CANCER, 2024, 24 (01)
  • [29] Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study
    Facchinetti, Francesco
    Bahleda, Rastislav
    Hollebecque, Antoine
    Loriot, Yohann
    Recondo, Gonzalo
    Bigot, Ludovic
    Olaussen, Ken A.
    Vassal, Gilles
    Michiels, Stefan
    Frias, Rosa L.
    Galissant, Justine
    Sourisseau, Tony
    Nicotra, Claudio
    Ngo-Camus, Maud
    Mahjoubi, Linda
    Lacroix, Ludovic
    Rouleau, Etienne
    Richon, Catherine
    Abou-Lovergne, Aurelie
    Deas, Olivier
    Auger, Nathalie
    De Baere, Thierry
    Deschamps, Frederic
    Solary, Eric
    Scoazec, Jean-Yves
    Angevin, Eric
    Eggermont, Alexander
    Andre, Fabrice
    Besse, Benjamin
    Thiery, Jean-Paul
    Soria, Jean-Charles
    Massard, Christophe
    Friboulet, Luc
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine
    Schiff, Rachel
    Jeselsohn, Rinath
    CANCER DISCOVERY, 2018, 8 (11) : 1352 - 1354
12345